Cat. No. 1485
Alternative Name: Docosatetraenylethanolamide
Chemical Name: N-(2-Hydroxyethyl)-7Z,10Z,13Z,16Z-d
Biological ActivityPotent endocannabinoid and anandamide (Cat. No. 1339) analog that activates CB1 receptors in microglia and binds to rat synaptosomal membranes (Ki = 34.4 nM). Cannabimimetic in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Walter et al (2001) Microglial cells produce endocannabinoids and express functional cannabinoid receptors: evidence that docosatetraenylethanolamide (DEA) is an additional endocannabinoid. Soc.Neurosci.Abstr. 634.16.
Barg et al (1995) Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur.J.Pharmacol. 287 145. PMID: 8749028.
Hanus et al (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J.Med.Chem. 36 3032. PMID: 8411021.
If you know of a relevant reference for DEA please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses DEA from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: DEA, supplier, Endogenous, CB1, agonists, Cannabinoids, Receptors, cb1r, Tocris Bioscience, CB1 Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Potent and selective CB2 partial agonist; orally biovailable
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.